抗癌平丸联合西妥昔单抗、伊立替康治疗晚期左半结直肠癌患者的效果  

Effects of Anticancer pills combined with Cetuximab and Irinotecan in e treatment of patients with advanced left colorectal cancer

作　　者：吴宏川 刘国军 WU Hongchuan;LIU Guojun(Department of Oncology of Fangcheng County Hospital of Traditional Chinese Medicine,Nanyang 473200 Henan,China;the Second Affiliated Hospital of Nanyang Medical College Anorectal department,Nanyang 473200 Henan,China)

机构地区：[1]方城县中医院肿瘤内科,河南南阳473200 [2]南阳医专第二附属医院肛肠科,河南南阳473200

出　　处：《中国民康医学》2023年第22期110-112,共3页Medical Journal of Chinese People’s Health

摘　　要：目的:观察抗癌平丸联合西妥昔单抗、伊立替康治疗晚期左半结直肠癌患者的效果。方法:回顾性分析2021年1月至2023年1月方城县中医院收治的116例晚期左半结直肠癌患者的临床资料,按照治疗方法不同将其分为研究组和对照组各58例。对照组采用伊立替康联合西妥昔单抗治疗,研究组在对照组基础上加用抗癌平丸治疗,共治疗8周。比较两组临床疗效,治疗前后肿瘤标志物[癌胚抗原(CEA)、糖类抗原19-9(CA19-9)]水平、免疫指标[免疫球蛋白A(IgA)、免疫球蛋白M(IgM)]水平、卡氏(KPS)评分,以及不良反应发生率。结果:研究组客观缓解率(ORR)为89.66%(52/58),高于对照组的75.86%(44/58),差异有统计学意义(P<0.05);治疗后,研究组CEA、CA19-9水平均低于对照组,差异有统计学意义(P<0.05);治疗后,研究组IgA、IgM水平和KPS评分均高于对照组,差异有统计学意义(P<0.05);两组皮疹、骨髓抑制、腹泻、肝肾功能异常等不良反应发生率比较,差异均无统计学意义(P>0.05)。结论:抗癌平丸联合西妥昔单抗、伊立替康治疗晚期左半结直肠癌患者可提高ORR、免疫指标水平和KPS评分,降低肿瘤标志物水平,效果优于西妥昔单抗联合伊立替康治疗。Objective:To observe effects of Anticancer pills combined with Cetuximab and Irinotecan in treatment of patients with advanced left colorectal cancer.Methods:The clinical data of 116 patients with advanced left colorectal cancer admitted to this hospital from January 2021 to January 2023 were retrospectively analyzed.According to different treatment methods,they were divided into study group and control group,58 cases in each.The control group was treated with Irinotecan combined with Cetuximab,while the study group was treated with Anticancer pills on the basis of those of the control group.After 8 weeks of treatment,the clinical efficacy,the tumor marker index levels[carcinoembryonic antigen(CEA),carbohydrate antigen 19-9(CA19-9)],the immune index levels[immunoglobulin A(IgA),immunoglobulin M(IgM)],the Karnofsky(KPS)score,and the incidence of adverse reactions were compared between the two groups before and after the treatment.Results:The objective response rate(ORR)of the study group was 89.66%(52/58),which was higher than 75.86%(44/58)of the control group,and the difference was statistically significant(P<0.05).After the treatment,the levels of CEA and CA19-9 in the study group were lower than those in the control group,and the differences were statistically significant(P<0.05).After the treatment,the levels of IgA,IgM and the KPS score in the study group were higher than those in the control group,and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions such as rash,bone marrow suppression,diarrhea,liver and kidney dysfunction between the two groups(P>0.05).Conclusions:Anticancer pills combined with Cetuximab and Irinotecan in the treatment of the patients with advanced left colorectal cancer can improve the ORR,the immune index levels and the KPS scores,and reduce the levels of tumor marker indexes.Moreover,it is superior to Cetuximab combined with Irinotecan treatment.

关 键 词：抗癌平丸 西妥昔单抗 伊立替康 晚期 结直肠癌 免疫功能 卡氏评分 

分 类 号：R735[医药卫生—肿瘤]